Skip to main content

Table 2 Independent favorable prognostic factor for intracranial PFS* and OS

From: Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Outcome Variable Hazard ratio 95% CI P
Intracranial PFS SRS and nivolumab 0.54 0.32–0.92 0.038
fmulti-fraction SRS 0.48 0.28–0.87 0.015
OS SRS and nivolumab 0.51 0.28–0.81 0.019
multi-fraction SRS 0.54 0.33–0.96 0.043
KPS >70 0.34 0.23–0.78 0.010
absent extracranial disease 0.50 0.29–0.81 0.018
  1. Abbreviations: OS, overall survival; PFS, progression-free survival;HR, hazard ratio; CI, confidence interval; *Variables with a significance of p < 0.05 at univariate analysis were included in the multivariate analysis. The following variables were evaluated: age, gender, Karnofsly Perforance Status (KPS) score, histology, extracranial disease status, systemic therapy, number of metastases, time to brain metasases development, conformity index, and irradiated volumes